Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Treatment: biologics
View through CrossRef
According to classification criteria, the spectrum of spondyloarthritis (SpA) covers axial SpA (axSpA), which includes non-radiographic axSpA and ankylosing spondylitis, and peripheral SpA, which overlaps with psoriatic arthritis. Management recommendations for many forms of SpA have been recently published. Treatment of patients with axSpA with active disease starts with a sufficient dose of non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks and preferably longer, in combination with exercise. In case of peripheral SpA, several disease-modifying antirheumatic drugs can be given, but these are not efficacious in axial disease. In case of insufficient response to NSAIDs for axSpA, biologic treatment can be added. The biologics most commonly used are TNF-blocking agents, but some other biologic agents seem to be beneficial in axial diseases as well, such as secukinumab (an IL-17 blocker). However, these new drugs have not yet been approved for axSpA at the time of writing this chapter.
Title: Treatment: biologics
Description:
According to classification criteria, the spectrum of spondyloarthritis (SpA) covers axial SpA (axSpA), which includes non-radiographic axSpA and ankylosing spondylitis, and peripheral SpA, which overlaps with psoriatic arthritis.
Management recommendations for many forms of SpA have been recently published.
Treatment of patients with axSpA with active disease starts with a sufficient dose of non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks and preferably longer, in combination with exercise.
In case of peripheral SpA, several disease-modifying antirheumatic drugs can be given, but these are not efficacious in axial disease.
In case of insufficient response to NSAIDs for axSpA, biologic treatment can be added.
The biologics most commonly used are TNF-blocking agents, but some other biologic agents seem to be beneficial in axial diseases as well, such as secukinumab (an IL-17 blocker).
However, these new drugs have not yet been approved for axSpA at the time of writing this chapter.
Related Results
Dual diagnosis
Dual diagnosis
Substance abuse and mental illness are concentrated in correctional populations. Further, nearly half of female inmates and one-third of male inmates with substance use disorders h...
Values-Based Involuntary Seclusion and Treatment
Values-Based Involuntary Seclusion and Treatment
This chapter gives a reflective account of a values-based model of involuntary psychiatric seclusion and treatment (henceforth “involuntary treatment”) adopted in the training mate...
Coercion in Community Mental Health Care
Coercion in Community Mental Health Care
The use of coercion is one of the defining issues of mental health care and has been intensely controversial since the very earliest attempts to contain and treat the mentally ill....
Empirically Supported Couple Therapies
Empirically Supported Couple Therapies
This article provides a comparative review of five empirically supported couple therapies: traditional behavioral couple therapy (behavioral marital therapy), cognitive behavioral ...
Management of Sickle Cell Pain
Management of Sickle Cell Pain
Abstract
While sickle cell disease (SCD) is uncommon in Europe and North America, SCD patients presenting for pain account for an outsized and prominent proportion o...
Prostate Cancer: the facts
Prostate Cancer: the facts
Abstract
Prostate cancer is the second leading cause of cancer death in men. Figures from the US show that the average male stands a one in five chance of developing...
Nature-Based Technologies for Wastewater Treatment and Bioenergy Production
Nature-Based Technologies for Wastewater Treatment and Bioenergy Production
An accessible ePub edition is available here
With 80% of wastewater globally discharged untreated and non-renewable energy resources rapidly depleti...
Understanding and Treating Depression
Understanding and Treating Depression
In any given year, 10 percent of the population - or about 21 million people - suffers from a depressive disorder. Most do not seek professional help although the great majority co...